VTAK (Catheter Precision, Inc.) was a micro-cap, low-float name that exploded onto the radar on July 7, 2026. The stock opened at $1.21, ripped to an intraday high of $1.74, and had surged over 85% from its previous close of $0.71, the kind of violent, low-float move that demands attention.
The catalyst was a combination of news indicators, including Flyte, Catheter Precision’s technology-enabled Regional Air Mobility subsidiary.
Flyte announced a strategic partnership with LifeVac, equipping its entire fleet of Cirrus Vision Jets with FDA-authorised airway clearance devices (an announcement that reinforced Flyte’s safety-first brand positioning and added to its growing profile as a differentiated player in regional private aviation). On the same day, news that Flyte had cleared over $1 million in revenue and surpassed 1,000 active users in the first half of 2026 gave the story real operational credibility, showing this was more than a concept, but a revenue-generating business scaling in real time.
A separate $2.2 million strategic investment announcement added further fuel, signalling outside confidence in the platform.
For a micro-cap float, that combination of a partnership announcement, a revenue milestone, and fresh investment news landing on the same day was more than enough to ignite the kind of retail-driven price action that followed.

